ImmuPharma PLC is a pharmaceutical development company listed since 2006 on AIM of the London Stock Exchange. The company is focusing on developing novel medicines with high sales potential in specialist markets with serious unmet need. ImmuPharma has five drug candidates in development, two platform technologies and approximately 70 patents. Lupuzor ™ is the company’s most advanced drug candidate and is a treatment for lupus, and life threatening auto immune disease. Lupuzor ™ has 'Gold Standard' approval from the US FDA for its Phase III trial with a Special Protocol Assessment and "Fast Track" designation. Lupuzor ™ has now commenced its Phase III pivotal trial.

London, GB
Size (employees)
10 (est)
Immupharma is headquartered in London, GB
Report incorrect company information

Immupharma Office Locations

Immupharma has offices in London, Mulhouse and Sarnen
London, GB (HQ)
50 Broadway
Mulhouse, FR
5 Rue du Rhône
Sarnen, CH
10 Poststrasse
Show all (3)
Report incorrect company information

Immupharma Financials and Metrics

Immupharma Financials

Immupharma's revenue was reported to be £164.78 k in FY, 2016

Revenue (FY, 2016)

164.8 k

Net income (FY, 2016)

(5.3 m)

EBITDA (FY, 2016)

(6.5 m)

EBIT (FY, 2016)

(6.6 m)

Market capitalization (31-Oct-2017)

123 m

Closing share price (31-Oct-2017)


Cash (31-Dec-2016)

1.9 m
Immupharma's current market capitalization is £123 m.
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016


63.2 k57.1 k22.1 m32.5 k16.8 k184.8 k76.4 k164.8 k

Revenue growth, %


Operating expense total

3.6 m4.6 m11.8 m4.2 m(3.8 m)3.6 m4.6 m6.8 m


(3.5 m)(4.5 m)10.3 m(4.1 m)3.9 m(4.1 m)(4.2 m)(3.3 m)(4.4 m)(6.5 m)
GBPY, 2016

Financial Leverage

1.2 x
Show all financial metrics
Report incorrect company information